SEC Form 4 · accession 0001144204-17-012518
China Biologic Products, Inc. · CBPO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Gao
Officer — Chief Executive Officer · Director
Period of report
Feb 28, 2017
Accepted (ET)
Mar 2, 2017 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Feb 28, 2017 | S | 62,604 | $100.69 | D | 449,396 | D | |
| Common StockF2,F4 | Mar 1, 2017 | S | 54,049 | $100.57 | D | 395,347 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 62,604 shares of common stock sold in the open market at a weighted average price of $100.69 per share on Februray 28, 2017. The Reporting Person intends to use the proceeds from the sale to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person and the exercise of certain stock options held by the Reporting Person.
- F2Represents 54,049 shares of common stock sold in the open market at a weighted average price of $100.57 per share on March 1, 2017. The Reporting Person intends to use the proceeds from the sale to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person and the exercise of certain stock options held by the Reporting Person.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $99.04 to $104.48, inclusive.*
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $100.00 to $102.57, inclusive.*
Remarks
* The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnotes 2 and 3.